Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
1–10
Headlines
10
Sources here
2
Companies here
3
Current section China Drug Manufacturers - Specialty & Generic news
Latest

finance.yahoo.com Market update

Top China Biopharma Stocks to Watch, According to Bernstein

Investing.com -- Bernstein has identified several China-based biopharmaceutical companies positioned to benefit from evolving drug development capabilities, with a focus on integrated platforms and service providers that support AI-enabled research and development workflows. Still guessing which names to buy? Our AI rebuilds its stock picks at the start of every month. The list is beating the market by …

Provider-linked mention 🇨🇳 China
Read at finance.yahoo.com
Sharemaestro market context Price below Trend Line 52 weeks -33.8% 600276 stored weekly price path from 3 Oct 2025 to 2 Oct 2026
Just inNext headlines
finance.yahoo.com Deals and strategy Provider-linked mention 🇨🇳 China

Novo Nordisk (CPSE:NOVO B) Licensed A Once Weekly Oral GLP 1 GIP Drug

Novo Nordisk (CPSE:NOVO B) entered an exclusive license with Hengrui Pharma for a once-weekly oral GLP-1/GIP dual agonist. Phase 3 CagriSema data delivered new weight management clinical results that add another late-stage asset to Novo Nordisk's pipeline. The CHMP issued a positive opinion backing …

600276 mentioned
Sharemaestro market context Price below Trend Line 52 weeks -33.8% 600276 stored weekly price path from 3 Oct 2025 to 2 Oct 2026
finance.yahoo.com Deals and strategy Main company 🇨🇳 China

Hengrui Pharma shares rise as Novo Nordisk signs $2.6 billion drug deal

Investing.com --Jiangsu Hengrui Pharmaceuticals (HK:1276) shares rose in Hong Kong on Tuesday after Novo Nordisk entered an agreement to license the Chinese drugmaker's experimental obesity and diabetes treatment in a deal worth up to $2.6 billion. Still guessing which names to buy? Our AI …

600276 main company
Sharemaestro market context Price below Trend Line 52 weeks -33.8% 600276 stored weekly price path from 3 Oct 2025 to 2 Oct 2026

Chronological news

Latest headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Market update Main company 🇨🇳 China

Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596

Novo Nordisk A/S HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties Bagsværd, Denmark, 29 September 2026 – …

600276 main company
Sharemaestro market context Price below Trend Line 52 weeks -33.8% 600276 stored weekly price path from 3 Oct 2025 to 2 Oct 2026
finance.yahoo.com Market update Provider-linked mention 🇨🇳 China

Jim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth”

During the lightning round of the September 10 episode of Mad Money, a caller asked if Kailera Therapeutics, Inc. (NASDAQ:KLRA) is a buy, sell, or hold. In response, Jim Cramer said: Okay, I actually know this, but okay, here's the problem. Let's say I …

600276 mentioned
Sharemaestro market context Price below Trend Line 52 weeks -33.8% 600276 stored weekly price path from 3 Oct 2025 to 2 Oct 2026
finance.yahoo.com Capital return Provider-linked mention 🇨🇳 China

Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion

SHANGHAI, Sept. 6, 2026 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) today announced an H-share repurchase plan, under which the company intends to repurchase its H-shares with an aggregate amount of up to HK$1 billion. The shares …

600196 mentioned
Sharemaestro market context Price above Trend Line 52 weeks -19.5% 600196 stored weekly price path from 3 Oct 2025 to 2 Oct 2026
finance.yahoo.com Earnings Provider-linked mention 🇨🇳 China

Fosun Pharma Announces 2026 Interim Results

Globalization Accelerates Value Realization of Innovative Drugs SHANGHAI, Aug. 25, 2026 /PRNewswire/ -- On August 25, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its interim results for 2026. In the first half of 2026 ("the Reporting Period", or 1H2026), the Company recorded …

600196 mentioned
Sharemaestro market context Price above Trend Line 52 weeks -19.5% 600196 stored weekly price path from 3 Oct 2025 to 2 Oct 2026
finance.yahoo.com Earnings Main company 🇨🇳 China

Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum

SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first half of 2026. During the reporting period, innovative drugs remained the Company's key growth driver, while globalization initiatives continued to validate the global value …

600276 main company
Sharemaestro market context Price below Trend Line 52 weeks -33.8% 600276 stored weekly price path from 3 Oct 2025 to 2 Oct 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context